Ulrich Dauer, PhD
Chief Executive Officer, Executive Director
As one of the founders, Ulrich Dauer previously worked for 14 years as CEO of 4SC AG, attracting multiple private and, upon the company’s listing at the Prime Standard segment of Deutsche Börse in 2005, public investors. Under his leadership, 4SC closed multiple industry partnerships with international biopharmaceutical companies. In subsequent leadership positions in the biotech industry, he executed in 2014 the €130 M trade sale of Activaero and later took up CEO positions of two privately held biotech companies.
Ulrich Dauer holds a PhD in Chemistry from the Julius-Maximilians University of Würzburg.
Chief Financial Officer, Executive Director
Mr. Schmid joins Vivoryon from InflaRx, where he served as Director Finance & Controlling supporting various financing transactions including a US IPO.
Prior to that role, Mr. Schmid spent nearly six years at T‐Systems International GmbH, where he most recently led the Global Deal & Business Support department. Florian Schmid began his career as certified Tax Advisor and Public Accountant at Arthur Andersen and Ernst & Young.
Mr. Schmid received a business degree from the Ludwig‐Maximilian‐University, Munich.
Michael Schaeffer, PhD
Chief Business Officer, Executive Director
Micheal Schaeffer is a highly experienced serial entrepreneur and was prior to joining our company, – amongst others – Founder, CEO and Managing Director of biotech companies, CRELUX GmbH and SiREEN AG. Following the acquisition of CRELUX by WuXiAppTec in 2016, Dr. Schaeffer was responsible for integrating CRELUX into the world-leading Shanghai based CRO with over 25,000 employees globally.
Michael Schaeffer received his PhD in Molecular Biology from Ludwig-Maximilians-Universität in Munich, Germany and is an exceptionally skilled Operations- and Innovation Manager.
Frank Weber, MD
Chief Medical Officer
Frank brings 30 years of experience in the pharmaceutical and life science industry. Prior to his position at Vivoryon, he served as Chief Medical Officer at Merck KGaA in Germany and Switzerland, before joining Californian InterMune (now Genentech/Roche) as Global Clinical Advisor. He started his career with various management positions in medical affairs and clinical development at American Cyanamid (Lederle), in 1991, USA and at Synthelabo (now Sanofi) ,1993 France.
Frank received his MD in Cancer Immunology at the Medical University Cologne, Germany.